BACKGROUND: Infections are an important concern in patients using immunosuppressive therapy for their inflammatory bowel disease (IBD). Diabetes affects nearly 10% of Americans. Whether it confers an additional risk with immunosuppression in IBD has not been examined previously. AIM: To examine the association between diabetes and infections with immunomodulator use in IBD METHODS: Using a validated, multi-institutional IBD cohort, we identified all patients who received at least one prescription for immunomodulators (thiopurines, methotrexate). Our primary outcome was infection within 1 year of the prescription of the immunomodulator. Multivariable logistic regression adjusting for relevant confounders was used to estimate the independent association with diabetes. RESULTS: Our study included 2766 patients receiving at least one prescription for immunomodulators among whom 210 (8%) developed an infection within 1 year. Patients who developed an infection were likely to be older, have more comorbidities, more likely to have received a prescription for steroids but similar in initiation of anti-TNF therapy within that year. Only 8% of those without an infection had diabetes compared to 19% of those who developed an infection within 1 year [odds ratio (OR) 2.74, 95% confidence interval (CI) 1.88-3.98, P < 0.001]. On multivariate analysis, diabetes was independently associated with a nearly two-fold increase in risk of infections (OR: 1.80, 95% CI: 1.20-2.68). There was no increase in risk of infections with addition of anti-TNF therapy (OR: 1.14, 95% CI: 0.80-1.63). CONCLUSION: Diabetes is an independent risk factor for infection in IBD patients using immunomodulator therapy.
BACKGROUND:Infections are an important concern in patients using immunosuppressive therapy for their inflammatory bowel disease (IBD). Diabetes affects nearly 10% of Americans. Whether it confers an additional risk with immunosuppression in IBD has not been examined previously. AIM: To examine the association between diabetes and infections with immunomodulator use in IBD METHODS: Using a validated, multi-institutional IBD cohort, we identified all patients who received at least one prescription for immunomodulators (thiopurines, methotrexate). Our primary outcome was infection within 1 year of the prescription of the immunomodulator. Multivariable logistic regression adjusting for relevant confounders was used to estimate the independent association with diabetes. RESULTS: Our study included 2766 patients receiving at least one prescription for immunomodulators among whom 210 (8%) developed an infection within 1 year. Patients who developed an infection were likely to be older, have more comorbidities, more likely to have received a prescription for steroids but similar in initiation of anti-TNF therapy within that year. Only 8% of those without an infection had diabetes compared to 19% of those who developed an infection within 1 year [odds ratio (OR) 2.74, 95% confidence interval (CI) 1.88-3.98, P < 0.001]. On multivariate analysis, diabetes was independently associated with a nearly two-fold increase in risk of infections (OR: 1.80, 95% CI: 1.20-2.68). There was no increase in risk of infections with addition of anti-TNF therapy (OR: 1.14, 95% CI: 0.80-1.63). CONCLUSION:Diabetes is an independent risk factor for infection in IBD patients using immunomodulator therapy.
Authors: Ashwin N Ananthakrishnan; Tianxi Cai; Guergana Savova; Su-Chun Cheng; Pei Chen; Raul Guzman Perez; Vivian S Gainer; Shawn N Murphy; Peter Szolovits; Zongqi Xia; Stanley Shaw; Susanne Churchill; Elizabeth W Karlson; Isaac Kohane; Robert M Plenge; Katherine P Liao Journal: Inflamm Bowel Dis Date: 2013-06 Impact factor: 5.325
Authors: Ashwin N Ananthakrishnan; Andrew Cagan; Tianxi Cai; Vivian S Gainer; Stanley Y Shaw; Susanne Churchill; Elizabeth W Karlson; Shawn N Murphy; Isaac Kohane; Katherine P Liao Journal: Clin Gastroenterol Hepatol Date: 2014-07-17 Impact factor: 11.382
Authors: L M A J Muller; K J Gorter; E Hak; W L Goudzwaard; F G Schellevis; A I M Hoepelman; G E H M Rutten Journal: Clin Infect Dis Date: 2005-06-16 Impact factor: 9.079
Authors: S Fuji; A Rovó; K Ohashi; M Griffith; H Einsele; M Kapp; M Mohty; N S Majhail; B G Engelhardt; A Tichelli; B N Savani Journal: Bone Marrow Transplant Date: 2016-04-04 Impact factor: 5.483
Authors: M M T J Broekman; M J H Coenen; G J Wanten; C J van Marrewijk; O H Klungel; A L M Verbeek; P M Hooymans; H-J Guchelaar; H Scheffer; L J J Derijks; D R Wong; D J de Jong Journal: Aliment Pharmacol Ther Date: 2017-09-15 Impact factor: 8.171
Authors: Vera E R Asscher; Quirine van der Vliet; Karen van der Aalst; Anniek van der Aalst; Eelco C Brand; Andrea E van der Meulen-de Jong; Bas Oldenburg; Marieke J Pierik; Bas van Tuyl; Nofel Mahmmod; P W Jeroen Maljaars; Herma H Fidder Journal: Int J Colorectal Dis Date: 2020-08-28 Impact factor: 2.571